1,001 research outputs found
Tedizolid (TR-701): A new oxazolidinone with enhanced potency
No full textIntroduction: Tedizolid phosphate (TR-701) is a new oxazolidinone prodrug that is transformed in the serum into the active drug tedizolid (TR-700). Tedizolid acts by inhibiting protein synthesis and has broad activity against Gram-positive pathogens, including strains that are resistant to linezolid. Areas covered: This review summarizes the currently available data on this new antimicrobial agent. In vitro activity, pharmacokinetics-pharmacodynamics, clinical efficacy and safety are all addressed. Expert opinion: Tedizolid will provide a useful addition to the antimicrobial armamentarium, particularly in complicated skin and skin structure infections, due to its high oral bioavailability and once-daily dosing. The results of future studies will serve to better position tedizolid among the newly approved agents for infections caused by Gram-positive organisms. © 2012 Informa UK, Ltd.[Anonymous], 2001, AM J INFECT CONTROL, V29, P404; Betriu C, 2010, ANTIMICROB AGENTS CH, V54, P2212, DOI 10.1128-AAC.01653-09; Bien P., 2010, 50 INT C ANT AG CHEM; Brown SD, 2010, ANTIMICROB AGENTS CH, V54, P2063, DOI 10.1128-AAC.01569-09; Chang S, 2003, NEW ENGL J MED, V348, P1342, DOI 10.1056-NEJMoa025025; Colak D, 2002, J ANTIMICROB CHEMOTH, V50, P397, DOI 10.1093-jac-dkf134; Colca JR, 2003, J BIOL CHEM, V278, P21972, DOI 10.1074-jbc.M302109200; Dreskin H, 2011, 51 INT C ANT AG CHEM; Falagas ME, 2006, J ANTIMICROB CHEMOTH, V58, P273, DOI 10.1093-jac-dkl219; Fluit AC, 2001, J CLIN MICROBIOL, V39, P3727, DOI 10.1128-JCM.39.10.3727-3732.2001; Fridkin SK, 2005, NEW ENGL J MED, V352, P1436, DOI 10.1056-NEJMoa043252; Gould IM, 2008, INT J ANTIMICROB AG, V31, P1, DOI 10.1016-S0924-8579(08)70002-5; Hiramatsu K, 1997, J ANTIMICROB CHEMOTH, V40, P135, DOI 10.1093-jac-40.1.135; Housman ST, 2011, 51 INT C ANT AG CHEM; Hsueh PR, 1999, INFECT CONT HOSP EP, V20, P828, DOI 10.1086-501592; Im WB, 2011, EUR J MED CHEM, V46, P1027, DOI 10.1016-j.ejmech.2011.01.014; Jacobson LM, 2009, PEDIATR INFECT DIS J, V28, P445, DOI 10.1097-INF.0b013e3181927891; Jones RN, 2009, J ANTIMICROB CHEMOTH, V63, P716, DOI 10.1093-jac-dkp021; Keel RA, 2011, 51 INT C ANT AG CHEM; Kirst HA, 1998, ANTIMICROB AGENTS CH, V42, P1303; Leach KL, 2007, MOL CELL, V26, P393, DOI 10.1016-j.molcel.2007.04.005; LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056-NEJM198807213190307; Lemaire S, 2009, J ANTIMICROB CHEMOTH, V64, P1035, DOI 10.1093-jac-dkp267; Livermore DM, 2009, J ANTIMICROB CHEMOTH, V63, P713, DOI 10.1093-jac-dkp002; Locke JB, 2009, ANTIMICROB AGENTS CH, V53, P5265, DOI 10.1128-AAC.00871-09; Louie A, 2011, ANTIMICROB AGENTS CH, V55, P3453, DOI 10.1128-AAC.01565-10; Mangili A, 2005, CLIN INFECT DIS, V40, P1058, DOI 10.1086-428616; Moellering RC, 2003, ANN INTERN MED, V138, P135; Moise PA, 2000, INT J ANTIMICROB AG, V16, pS31; Munoz KA, 2011, 21 EUR C CLIN MICR I; Prasad JV, 2007, CURR OPIN MICROBIOL, V10, P454, DOI 10.1016-j.mib.2007.08.001; Prokocimer P, 2008, 48 INT C ANT AG CHEM; Prokocimer P, 2011, ANTIMICROB AGENTS CH, V55, P583, DOI 10.1128-AAC.00076-10; Ramsey AM, 2009, INFECT CONT HOSP EP, V30, P184, DOI 10.1086-593956; Rodriguez-Avial I, 2012, J ANTIMICROB CHEMOTH, V67, P167, DOI 10.1093-jac-dkr403; Sakoulas G, 2004, J CLIN MICROBIOL, V42, P2398, DOI 10.1128-JCM.42.6.2398-2402.2004; Garcia MS, 2010, JAMA-J AM MED ASSOC, V303, P2260, DOI 10.1001-jama.2010.757; Schaadt R, 2009, ANTIMICROB AGENTS CH, V53, P3236, DOI 10.1128-AAC.00228-09; Shaw KJ, 2008, ANTIMICROB AGENTS CH, V52, P4442, DOI 10.1128-AAC.00859-08; SMALL PM, 1990, ANTIMICROB AGENTS CH, V34, P1227; UTTLEY AHC, 1989, EPIDEMIOL INFECT, V103, P173; van Hal SJ, 2011, EUR J CLIN MICROBIOL, V30, P603, DOI 10.1007-s10096-010-1128-3; VOSS A, 1994, EUR J CLIN MICROBIOL, V13, P50, DOI 10.1007-BF02026127; Woods CW, 2004, CLIN INFECT DIS, V38, P1188, DOI 10.1086-383027; Yamaki J, 2011, ANTIMICROB AGENTS CH, V55, P4432, DOI 10.1128-AAC.00122-11; Yum JH, 2010, ANTIMICROB AGENTS CH, V54, P5381, DOI 10.1128-AAC.00728-10; Zetola N, 2005, LANCET INFECT DIS, V5, P275, DOI 10.1016-S1473-3099(05)70112-214171
Erratum: Allen, G.R., Erdmann, M.V. & Purtiwi, P.D. (2017): Author Purtiwi, P.D. is spelled Pertiwi, P.D.
No full textAllen, G.R., Erdmann, M.V. & Purtiwi, P.D. (2017) Descriptions of four new species of damselfishes (Pomacentridae) in the Pomacentrus philippinus complex from the tropical western Pacific Ocean. Journal of the Ocean Science Foundation, 25, 47–76.
corrected spelling of third author’s name to:
Allen, G.R., Erdmann, M.V. & Pertiwi, P.D. (2017) Descriptions of four new species of damselfishes
(Pomacentridae) in the Pomacentrus philippinus complex from the tropical western Pacific Ocean. Journal of the Ocean Science Foundation, 25, 47–76
The philosophy poetry of G.R. Derzhavin: the contrast of life and death
No full textThis article is devoted to the eshatological philosophical concept of the G.R. Derzhavins’ poetry. The author describes the presentation of the theme of death and its artistic transformation in the works of the poet as the reception of the Orthodox tradition, a kind of the cultural memory
The construction of Karen Karnak: The multi-author-function
No full textThis thesis is situated within the comparatively recent developments of Web 2.0 and the emergence of interactive WikiMedia, and explores the mode of authorship within a Read/Write culture compared to that of a Read/Only tradition. The hypothesis of this study is that the role of the audience has become merged with the author, and as such, represents new functions and attributes, distinct from a more conventional concept of authorship, in which the roles of audience and author are more separate. Read/Write and participatory culture, as defined by this study, is focused on collaboration, and includes the influences of D.I.Y. culture, Open-Source practices and the production of text by multiple authors. Multi-authorship presents a re-thinking of several concepts which support the notion of the individual author, since the focus of multi-authorship is not on attribution and ownership of a finished text, but on the continued malleability of a text. Modes of multi-authorship, demonstrated in the use of the pseudonyms Alan Smithee and Karen Eliot, represent declarative authors whose names signify multiple origins, whilst concurrently indicating a distinct body of work. The function of these names form an important context to this study, since primary research involves the construction of an experimental mode of multi-authorship utilising WikiMedia technology and the interaction of thirty nine participants, who are invited to create a body of work under the collective pseudonym Karen Karnak. The data generated by this experiment is analysed using aspects of Michel Foucault's author-function to identify and determine power structures inherent in the WikiMedia context. The interplay of power structures, including concepts such as identity, ownership and the body of work, affect the resulting mode of authorship and contribute to the construction of Karen Karnak, suggesting further areas of research into the emerging multi-author
Spectral properties of Andreev reflection from quantum turbulence in 3He-B: What do they tell about turbulent fluctuations?
No full textOne of the experimental techniques developed to measure quantum turbulence at low temperatures in 3He-B utilizes the Andreev reflection of thermal quasiparticle excitations from quantized vortices and vortex structures. We present the results of theoretical, numerical, and experimental study of Andreev scattering from quantum turbulence in 3He-B. We analyze the spectral properties of the Andreev reflection and compare these with the spectral properties of superfluid turbulence, and discuss the physical mechanisms responsible for the scaling of spectral densities. Finally, we discuss the relation between our findings and related observables in ordinary turbulence
Geographic profiling in Nazi Berlin: fact and fiction
No full textGeographic profiling uses the locations of connected crime sites to make inferences about the probable location of the offender’s ‘anchor point’ (usually a home, but sometimes a workplace). We show how the basic ideas of the method were used in a Gestapo investigation that formed the basis of a classic German novel about domestic resistance to the Nazis during the Second World War. We use modern techniques to re-analyse this case, and show that these successfully locate the Berlin home address of Otto and Elise Hampel, who had distributed hundreds of anti-Nazi postcards, after analysing just 34 of the 214 incidents that took place before their arrest. Our study provides the first empirical evidence to support the suggestion that analysis of minor terrorism-related acts such as graffiti and theft could be used to help locate terrorist bases before more serious incidents occur
Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia
No full textIntroduction: Hospital-acquired pneumonia is a common infection, associated with substantial mortality. Despite the increasing prevalence of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA), approved treatment options for this pathogen are limited. Areas covered: This article reviews the pharmacokinetics, dosing, preclinical studies and clinical efficacy, and safety of telavancin, with a particular focus on results from trials in nosocomial pneumonia. PubMed and Congress websites were searched for relevant articles published between 2003 and 2010. Expert opinion: Telavancin is a lipoglycopeptide antibiotic with rapid, bactericidal activity against MRSA, and may provide another option for the treatment of nosocomial pneumonia, owing to Gram-positive pathogens. © 2011 Informa UK, Ltd.American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P388, DOI DOI 10.1164-RCCM.200405-644ST; Andrews J, 2007, J ANTIMICROB CHEMOTH, V60, P677, DOI 10.1093-jac-dkm242; *AST PHARM INC, 2009, VIBATIV TEL INJ; Barcia-Macay M, 2008, J ANTIMICROB CHEMOTH, V61, P1288, DOI 10.1093-jac-dkn120; Barriere Steven, 2004, Journal of Clinical Pharmacology, V44, P689, DOI 10.1177-0091270004266620; Boselli E, 2005, CRIT CARE MED, V33, P1529, DOI 10.1097-01.CCM.0000168206.59873.80; Chang FY, 2003, MEDICINE, V82, P333, DOI 10.1097-01.md.0000091184.93122.09; Conte JE, 2002, ANTIMICROB AGENTS CH, V46, P1475, DOI 10.1128-AAC.46.5.1475-1480.2002; Corey GR, 2009, NAT REV DRUG DISCOV, V8, P929, DOI 10.1038-nrd3051; Corey GR, 2010, CLIN INFECT DIS, V51, P641, DOI 10.1086-655827; Cruciani M, 1996, J ANTIMICROB CHEMOTH, V38, P865; *CUB PHARM INC, 2010, CUB DAPT INJ PACK IN; Draghi DC, 2008, ANTIMICROB AGENTS CH, V52, P2383, DOI 10.1128-AAC.01641-07; Draghi DC, 2008, J ANTIMICROB CHEMOTH, V62, P116, DOI 10.1093-jac-dkn124; File TM, 2010, CLIN INFECT DIS, V51, P1395, DOI 10.1086-657313; Freire AT, 2010, DIAGN MICR INFEC DIS, V68, P140, DOI 10.1016-j.diagmicrobio.2010.05.012; Gander S, 2005, J ANTIMICROB CHEMOTH, V56, P337, DOI 10.1093-jac-dki198; Georges H, 1997, EUR J CLIN MICROBIOL, V16, P385, DOI 10.1007-BF01726369; Goldberg MR, 2010, PHARMACOTHERAPY, V30, P35, DOI 10.1592-phco.30.1.35; Goldberg MR, 2010, PHARMACOTHERAPY, V30, P806, DOI 10.1592-phco.30.8.806; Goldstein EJC, 2004, ANTIMICROB AGENTS CH, V48, P2149, DOI 10.1128-ACC.48.6.2149-2152.2004; Gonzalez C, 1999, CLIN INFECT DIS, V29, P1171, DOI 10.1086-313440; Gotfried MH, 2008, ANTIMICROB AGENTS CH, V52, P92, DOI 10.1128-AAC.00875-07; Gradelski E, 2001, INT J ANTIMICROB AG, V18, P43, DOI 10.1016-S0924-8579(01)00343-0; Hatano K, 2007, J ANTIBIOT, V60, P709; Hegde SS, 2004, ANTIMICROB AGENTS CH, V48, P3043, DOI 10.1128-AAC.48.8.3043-3050.2004; Heyland DK, 1999, AM J RESP CRIT CARE, V159, P1249; Hidayat LK, 2006, ARCH INTERN MED, V166, P2138, DOI 10.1001-archinte.166.19.2138; Higgins DL, 2005, ANTIMICROB AGENTS CH, V49, P1127, DOI 10.1128-AAC.49.3.1127-1134.2005; Honeybourne D, 2003, J ANTIMICROB CHEMOTH, V51, P1431, DOI 10.1093-jac-dkg262; Kalil AC, 2010, CRIT CARE MED, V38, P1802, DOI 10.1097-CCM.0b013e3181eb3b96; Kiem S, 2008, ANTIMICROB AGENTS CH, V52, P24, DOI 10.1128-AAC.00133-06; King A, 2004, J ANTIMICROB CHEMOTH, V53, P797, DOI 10.1093-jac-dkh156; Klevens RM, 2006, CLIN INFECT DIS, V42, P389, DOI 10.1086-499367; Kollef MH, 1998, CHEST, V113, P412, DOI 10.1378-chest.113.2.412; Kollef MH, 2005, CHEST, V128, P3854, DOI 10.1378-chest.128.6.3854; KUNKEL M, 2010, INF DIS SOC AM 48 AN; LAMER C, 1993, ANTIMICROB AGENTS CH, V37, P281; Leadbetter MR, 2004, J ANTIBIOT, V57, P326; Leonard SN, 2008, PHARMACOTHERAPY, V28, P458, DOI 10.1592-phco.28.4.458; Leuthner KD, 2006, J ANTIMICROB CHEMOTH, V58, P338, DOI 10.1093-jac-dkl235; Levine DP, 2006, CLIN INFECT DIS, V42, pS5, DOI 10.1086-491709; Liu C, 2011, CLIN INFECT DIS, V52, pE18, DOI 10.1093-cid-ciq146; Lodise TP, 2008, ANTIMICROB AGENTS CH, V52, P3315, DOI 10.1128-AAC.00113-08; Lodise TP, 2007, ANTIMICROB AGENTS CH, V51, P3731, DOI 10.1128-AAC.00101-07; Lodise TP, 2008, ANTIMICROB AGENTS CH, V52, P2300, DOI 10.1128-AAC.01110-07; Lodise TP, 2009, CLIN INFECT DIS, V49, P507, DOI 10.1086-600884; Luna CM, 1997, CHEST, V111, P676, DOI 10.1378-chest.111.3.676; Lunde CS, 2009, ANTIMICROB AGENTS CH, V53, P3375, DOI 10.1128-AAC.01710-08; Madrigal AG, 2005, ANTIMICROB AGENTS CH, V49, P3163, DOI 10.1128-AAC.49.8.3163-3165.2005; Mendes RE, 2010, INT J ANTIMICROB AG, V36, P374, DOI 10.1016-j.ijantimicag.2010.05.016; Mimoz O, 2006, INTENS CARE MED, V32, P775, DOI 10.1007-s00134-006-0136-3; Nannini EC, 2008, EXPERT OPIN PHARMACO, V9, P2197, DOI 10.1517-14656566.9.12.2197 ; Nguyen HA, 2009, ANTIMICROB AGENTS CH, V53, P1434, DOI 10.1128-AAC.01145-08; Odenholt I, 2007, ANTIMICROB AGENTS CH, V51, P3311, DOI 10.1128-AAC.01470-06; Pace JL, 2003, ANTIMICROB AGENTS CH, V47, P3602, DOI 10.1128-AAC.47.11.3602-3604.2003; Pertel PE, 2008, CLIN INFECT DIS, V46, P1142, DOI 10.1086-533441; Pfaller MA, 2010, J ANTIMICROB CHEMOTH, V65, P2396, DOI 10.1093-jac-dkq335; *PFIZ INC, 2010, ZYVOX LIN INJ LIN TA; Powers JH, 2004, CHEST, V126, P314, DOI 10.1378-chest.126.1.314; Putnam SD, 2010, DIAGN MICR INFEC DIS, V67, P359, DOI 10.1016-j.diagmicrobio.2010.03.009; Reyes N, 2006, J ANTIMICROB CHEMOTH, V58, P462, DOI 10.1093-jac-dkl222; Reyes N, 2005, ANTIMICROB AGENTS CH, V49, P4344, DOI 10.1128-AAC.49.10.4344-4346.2005; Rodvold KA, 2009, ANTIMICROB AGENTS CH, V53, P3294, DOI 10.1128-AAC.00144-09; Rotstein C, 2008, CAN J INFECT DIS MED, V19, P19; Rubinstein E, 2011, CLIN INFECT DIS, V52, P31, DOI 10.1093-cid-ciq031; Rybak MJ, 2006, CLIN INFECT DIS, V42, pS35, DOI 10.1086-491712; Sader HS, 2009, ANTIMICROB AGENTS CH, V53, P4127, DOI 10.1128-AAC.00616-09; Safdar N, 2005, CRIT CARE MED, V33, P2184, DOI 10.1097-01.CCM.0000181731.53912.D9; Saravolatz LD, 2007, J ANTIMICROB CHEMOTH, V60, P406, DOI 10.1093-jac-dkm211; Shaw JP, 2010, ANTIMICROB AGENTS CH, V54, P3365, DOI 10.1128-AAC.01750-09; Shaw JP, 2005, ANTIMICROB AGENTS CH, V49, P195, DOI 10.1128-AAC.49.1.195-201.2005; Silverman JA, 2005, J INFECT DIS, V191, P2149, DOI 10.1086-430352; Sivagnanam S, 2003, CRIT CARE, V7, P119, DOI 10.1186-cc1871; Soriano A, 2008, CLIN INFECT DIS, V46, P193, DOI 10.1086-524667; Steinkraus G, 2007, J ANTIMICROB CHEMOTH, V60, P788, DOI 10.1093-jac-dkm258; Stryjewski ME, 2006, ANTIMICROB AGENTS CH, V50, P862, DOI 10.1128-AAC.50.3.862-867.2006; Stryjewski ME, 2007, CLIN INFECT DIS, V44, P190, DOI 10.1086-510386; Stryjewski ME, 2008, CLIN INFECT DIS, V46, P1683, DOI 10.1086-587896; Stryjewski ME, 2005, CLIN INFECT DIS, V40, P1601, DOI 10.1086-429914; Stucki A, 2006, ANTIMICROB AGENTS CH, V50, P770, DOI 10.1128-AAC.50.2.770-773.2006; Sun HK, 2006, ANTIMICROB AGENTS CH, V50, P788, DOI 10.1128-AAC.50.2.788-790.2006; Tice AD, 2003, J ANTIMICROB CHEMOTH, V51, P1261, DOI 10.1093-jac-dkg186; Torres A, 2009, INTENS CARE MED, V35, P9, DOI 10.1007-s00134-008-1336-9; Tsuji BT, 2008, DIAGN MICR INFEC DIS, V60, P441, DOI 10.1016-j.diagmicrobio.2007.11.011; Wang GQ, 2006, J CLIN MICROBIOL, V44, P3883, DOI 10.1128-JCM.01388-06; Wong SL, 2010, PHARMACOTHERAPY, V30, P136, DOI 10.1592-phco.30.2.136; Wunderink RG, 2003, CHEST, V124, P1789, DOI 10.1378-chest.124.5.1789; *WYETH PHARM INC, 2010, TYGACIL TIG FOR INJ; 2009, DA 22 110 VIBATIV TE55
Corrigendum: EEG beta suppression and low gamma modulation are different elements of human upright walking
No full textA corrigendum on EEG beta suppression and low gamma modulationare different elements of human upright walking by Seeber,M.,Scherer,R.,Wagner,J.,Solis-Escalante,T.,andMüller-Putz,G.R.(2014)Front.Hum. Neurosci.8:485.doi:10.3389/fnhum.2014.00485Biomechanical EngineeringMechanical, Maritime and Materials Engineerin
Refinement of solutions to the linear complimentarity problem
No full textNash equilibrium;game theaory;matrices
High-performance, Cost-effective 3D Stacked Wide-Operand Adders
No full textThrough-Silicon Vias (TSV) based 3D Stacked IC (3D-SIC) technology introduces new design opportunities for wide operand width addition units. Different from state of the art direct folding proposals we introduce two cost-effective 3D Stacked Hybrid Adders with identical tier structure, which potentially makes the manufacturing of hardware wide-operand fast adders a reality. An N-bitadder implemented on a K identical tier stacked IC performs in parallel two N=K-bit additions on each tier according to the anticipated computation principle. Inter-tier carry signals performing the appropriate sum selection are propagated by TSVs. The practical implications of direct folding and of our hybrid carry-select/prefix approaches are evaluated by a thorough case study on 65nm CMOS 3D adder implementations, for operand sizes up to 4096 bits and 16 tiers. Our simulations indicate that in almost all configurations at least one of the two proposed 3D stacked hybrid approaches is faster than the fastest 3D folding approach. When considering an appropriate metric for 3D designs, i.e., the delay-footprint-heterogeneity product, the hybrid adders substantially outperform the folding counterparts by a factor in-between 1:67 and 23:95.Accepted Author ManuscriptComputer Engineerin
- …
